EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted hope: new drug tackles tough lung cancer in small trial
Disease control Recruiting nowThis study tests a drug called teniposide in 15 people with advanced small cell lung cancer that has a specific gene change (c-Myc) and has stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and control the disease. Participants must be in…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
New hope for tough lung cancer: triple therapy trial launches
Disease control Recruiting nowThis early-phase study is for people with extensive-stage small cell lung cancer whose disease persisted, returned, or got worse after standard chemotherapy. The trial combines an experimental drug (iadademstat) with targeted radiation and an immunotherapy (atezolizumab) to see i…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New hope for aggressive lung cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding extra drugs to a standard chemotherapy plus ivonescimab regimen can better shrink tumors in people with extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups. The …
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Promising combo aims to stall lung cancer growth in Late-Stage patients
Disease control Recruiting nowThis study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can keep extensive-stage small cell lung cancer from growing. About 35 adults who have already received initial chemotherapy and immunotherapy will re…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a drug called sacituzumab govitecan against standard treatments for people with extensive stage small cell lung cancer that has already been treated once. About 695 participants will be randomly assigned to receive either the study drug or usual care. The main go…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for Hard-to-Treat cancers: IDE161 trial opens
Disease control Recruiting nowThis early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer) that have not responded to other treatments. The main goals are to check safety, find the right…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for advanced lung cancer: drug combo plus radiation shows promise
Disease control Recruiting nowThis study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. It combines the drug tislelizumab with chemotherapy, followed by chest radiation, then maintenance therapy. The goal is to see how long the cancer stays…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New triple therapy aims to slow aggressive lung cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer growing. About 56 adults who have not had prior treatment for this advanced lung canc…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters late-stage trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combi…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 01, 2026 16:01 UTC